Pacific Bio (PACB) Tops Q4 EPS by 1c

Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.27), $0.01 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $58.36 million versus the consensus estimate of $56.96 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Goldman "broadly" raises estimates for LTL and truckload stocks
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance